

Information on this form is available at www.uspto.gov →

Approved for use through 12/31/2012. OMB Control No. 0705-0188
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE
This form is available at www.uspto.gov. Persons are referred to the Internet to a collection of information unless it displays a valid OMB control number.


TRANSMITTAL FORM <i>(to be used for all correspondence after initial filing)</i>	Application Number	09/943,286	
	Filing Date	August 30, 2001	
	First Named Inventor	NUNOMURA	
	Group Art Unit	To be assigned	
	Examiner Name	To be assigned	
Total Number of Pages in This Submission	19	Attorney Docket Number	GP104-03.CN1

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input checked="" type="checkbox"/> Response to Notice to Comply (2 pgs.)	<input type="checkbox"/> Licensing related Papers	<input type="checkbox"/> Appeal Communication to Group (After Notice of Appeal, Brief, etc.)
<input checked="" type="checkbox"/> Sequence Listing on paper (9 pgs.)	<input type="checkbox"/> Petition	<input type="checkbox"/> Proprietary Information
<input checked="" type="checkbox"/> Sequence Listing Diskette	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Status Letter
<input checked="" type="checkbox"/> Sequence Listing Verification	<input type="checkbox"/> Power of Attorney, Revocation, Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	1. Return Copy of Notice to Comply (2 pgs.)
<input checked="" type="checkbox"/> Information Disclosure Statement (2 pgs.)	<input type="checkbox"/> Request for Refund	2. Copies of 9 Cited References
<input checked="" type="checkbox"/> PTO/SB/08 (in duplicate 4 pgs. total)	<input type="checkbox"/> CD, Number of CD(s) _____	3. Return Receipt Postcard
<input type="checkbox"/> Certified Copy of Priority Document(s)		
<input type="checkbox"/> Response to Missing Parts, Incomplete Application	Remarks	
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	The Commissioner is hereby authorized to charge any fee due in connection with this filing to Deposit Account No. 07-0835 in the name of Gen-Probe Incorporated.	

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	Michael J. Gilly, Reg. No. 42,579
Signature	
Date	December 17, 2001

CERTIFICATE OF MAILING			
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20531 on this date December 17, 2001			
Typed or printed name		Michael J. Gilly, Reg. No. 42,579	
Signature		Date	December 17, 2001

Copyright © 2001 by the United States Patent and Trademark Office. This work may be reproduced for non-commercial use without charge. Any other use without the express written permission of the United States Patent and Trademark Office is prohibited. This form is available at www.uspto.gov. Persons are referred to the Internet to a collection of information unless it displays a valid OMB control number.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Office Patent Application of:)	Group Art Unit: To be assigned
)	
NUNOMURA)	Examiner: To be assigned
)	
Serial No. 09/943,286)	Atty. Docket No. GP104-03.CN1
)	
Filed: August 30, 2001)	
)	
For: POLYNUCLEOTIDE)	
AMPLIFICATION METHOD)	

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER C.F.R. § 1.97(b) & (c)**

Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Applicant brings to the Examiner's attention the references listed on the attached form PTO/SB/08 (submitted in duplicate) for consideration in connection with the examination of the above-identified application. A copy of each cited reference is enclosed.

This Information Disclosure Statement is being submitted under 37 C.F.R. § 1.97(b) before the mailing of a first Office action on the merits.

If Applicant is mistaken, and a first Office action on the merits was mailed on or before the certified mailing date of this Information Disclosure Statement, as indicated on the enclosed Transmittal Form, then Applicant requests that this Information Disclosure Statement be treated as a submission under 37 C.F.R. § 1.97(c) and that the fee due under 37 C.F.R. § 1.17(p) be charged to Deposit Account No. 07-0835 in the name of Gen-Probe Incorporated.

IDS


Serial No. 09/943,286
Atty. Docket No. GP104-03.CN1

Applicant respectfully requests that the Examiner indicate consideration of the cited references by returning a copy of the attached form PTO/SB/08 with the Examiner's initials or other appropriate marks.

Respectfully Submitted,

Date: December 17, 2001

By:



Michael J. Gilly
Registration No. 42,579
Agent for Applicant

GEN-PROBE INCORPORATED
Patent Department
10210 Genetic Center Drive
San Diego, California 92121
PH: (858) 410-8657
FAX: (858) 410-8928

Complete if Known

Application Number	09/943,286
Filing Date	August 30, 2001
First Named Inventor	NUNOMURA
Group Art Unit	To be assigned
Examiner Name	To be assigned
Attorney Docket Number	GP104-03.CN1

(use as many sheets as necessary)

Sheet	1	of	2
-------	---	----	---

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS


[illegible]

Examiner
Signature

Date	
Considered	

*EXAMINER: In a reference considered whether or not citation is in conformance with MPEP 609. Draw, in through notation, list, in conformance and in a copy based on a copy of this form with next communication to applicant.

³ The publication designation number. (See attached Kinds of U.S. Patent Documents.) *Enter Off for that issued document by the two-letter code W.P. Standard STG. ⁴For Japanese patent documents the month and year of the receipt of the Emperor must precede the serial number for patent documents. Kind of currency for the attachment symbol was included in the document identifier for the standard STG. For example, "AJP 0011" indicates a Japanese mark type I, first class, and the attachment Standard.



Substitute for form 1449b PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/943,286
		Filing Date	August 30, 2001
		First Named Inventor	NUNOMURA
		Group Art Unit	To be assigned
		Examiner Name	To be assigned
		Attorney Docket Number	GP104-03.CN1
Sheet	2	of	2

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Class	Other Art	Include name of the author (in CAPITAL LETTERS); title of the article (when appropriate); title of the book, magazine, journal, serial, symposium, catalog, etc.; date, page(s); volume-issue number(s); publisher, city and/or country where published	
		ERLICH et al., "The Design and Optimization of the PCR", PCR Technology, 1989, Chp. 1, pp. 14-15, Stockton Press, US, XP002183252	
		INNIS et al., "PCR Protocols - A Guide to Method and Applications", 1989, pp. 10, Academic Press, San Diego, US, XP002183253	
		KELLOGG et al., "Quantitation of HIV-1 Proviral DNA Relative to Cellular DNA by the Polymerase Chain Reaction", Anal. Biochem., Sept. 1990, 189(2):202-208	
		PIATAK et al., "Quantitative Competitive Polymerase Chain Reaction for Accurate Quantitation of HIV DNA and RNA Species", BioTechniques, Jan. 1993, 14(1):70-81	
		VAN GEMEN et al., "The One-tube Quantitative HIV-1 RNA NASBA: Precision, Accuracy, and Application", PCR Methods Appl., Feb. 1995, 4(4):S177-S184	
		WONG-STAAAL et al., "Human immunodeficiency virus type 1, isolate BH10, genome", EMBL Online Database, May 1992, XP002183254 (Abstract)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER'S SIGNATURE: This field is used to indicate whether or not the statement is in compliance with MPEP 609. Draw a line through statement if not in compliance and not in compliance with the form with next communication to applicant.

*Include the names and addresses of Applicant's legal representatives (English and/or Japanese Translations attached).

Be sure to submit the statement to the appropriate office. Time will vary depending on the needs of the individual case. Any comments on the statement should be submitted to the appropriate office. U.S. Patent and Trademark Office, Washington, D.C. 20503.
U.S. PATENT AND TRADEMARK OFFICE, 1500 PENNSYLVANIA AVENUE, N.W., WASHINGTON, D.C. 20503